Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

  • Pharma
  • January 4, 2025
  • 60 views
Licences of 36 TN drug stores revoked

Chennai:  The Tamil Nadu drug control administration has revoked the licences of 36 retailers and wholesalers across the state for selling habit-forming drugs, opioid-based formulations used for anxiety or pain…

  • Pharma
  • January 4, 2025
  • 73 views
Dabur India expects low single-digit revenue growth in Q3

Dabur India on Friday said it expects to garner “low single-digit growth” in terms of consolidated revenue during the December quarter and a “flattish” operating profit growth. The company also…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aster Volunteers’ 50th Mobile Clinic Milestone, unmatched in Medical Philanthropy

Aster Volunteers’ 50th Mobile Clinic Milestone, unmatched in Medical Philanthropy

Licences of 36 TN drug stores revoked

Licences of 36 TN drug stores revoked

Dabur India expects low single-digit revenue growth in Q3

Dabur India expects low single-digit revenue growth in Q3

Pharma teachers faking profiles at multiple institutions, face being blacklisted

Pharma teachers faking profiles at multiple institutions, face being blacklisted

Biocon arm Biocon Pharma receives approval for Tacrolimus capsules in China

Biocon arm Biocon Pharma receives approval for Tacrolimus capsules in China

This multibagger pharma stock jumped 9% today; stock up 10x in 21 months

This multibagger pharma stock jumped 9% today; stock up 10x in 21 months